Company: WHWK
Filing Date: 2025-03-31
Form Type: S-3
Source: 0001193125-25-068942
Chunk: 21

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-31
Form: S-3
Chunk 21
---
al, M.D., a director of our Company, is the             
 Chief Investment Officer and Managing Member of Acuta Partners. Each of Acuta Partners and Dr. Dalal has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and 
 Dr. Dalal disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein. The principal business address of each of Acuta Capital is  
 c/o Acuta Capital Partners, LLC, 255 Shoreline Drive, Suite 515, Redwood City, California 94065.                                                                                                                                                     |

| 12. | Consists of (i) 1,250,000 shares of common stock purchased in the Private Placement by WZCUBE LLC; and (ii)                                                                                                                                      
 6,799 shares of common stock issuable upon the exercise of options within 60 days of March 4, 2025. Baiteng Zhao, Ph.D., a director of our Company, is the manager of WZCUBE LLC and exercises investment and voting power over the shares held. 
 Dr. Zhao disclaims beneficial ownership of the shares held by WZCUBE LLC, except to the extent of his pecuniary interest therein. The principal business address for WZCUBE LLC and Dr. Zhao is c/o Whitehawk Therapeutics, 2 Headquarters       
 Plaza, East Building, 11th Floor, Morristown, NJ 07960.                                                                                                                                                                                          |

| 13. | Consists of 833,000 shares of common stock purchased in the Private Placement by Tae Han, Ph.D. The principal 
 address of Dr. Han is 20424 NE 120th St, Redmond WA 98053.                                                    |

| 14. | Consists of (i) 100,000 shares of common stock purchased in the Private Placement by Mr. Ball, our Chief                                                                                                                            
 Technical Operations Officer; (ii) 102,853 shares of common stock held directly by Mr. Ball; and (iii) 202,891 shares of common stock issuable upon the exercise of options within 60 days of March 4, 2025. The principal business 
 address for Mr. Ball is c/o Whitehawk Therapeutics, 2 Headquarters Plaza, East Building, 11th Floor, Morristown, NJ 07960.                                                                                                          |